| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.11. | Abbott's Tectonic test looks to shift artery disease treatment with 'early' win | ||
| 03.11. | Rhythm doubles down on LG Chem obesity license, raising payout to as much as $855M | ||
| 03.11. | Philips sets aside $322M for proposed DOJ settlement over sleep apnea device recall | ||
| 03.11. | AbbVie abandons phase 2 solid tumor drug over 'limited benefit' | ||
| 03.11. | Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate | ||
| 03.11. | BioArctic left out in the cold as Novartis walks away from $800M neuro collab | ||
| 02.11. | FDA grants uniQure's Huntington's gene therapy priority review, teeing up 'defining milestone' | ||
| 02.11. | OpenAI-funded Biossil snags Theriva's unwanted antibiotic degrader portfolio for up to $91M | ||
| 02.11. | Teva ends trial of one of its original line-up of innovative meds over futility | ||
| 02.11. | FDA dims Bright Minds' outlook with partial hold on seizure trial over toxicity in mice | ||
| 02.11. | Lower dose of Tiziana's MS drug reduces neuroinflammation, while higher dose struggles | ||
| 02.11. | China's InventisBio delivers competitive TYK2 data in phase 3 psoriasis win | ||
| 30.10. | Gilead reveals partial clinical hold on 2 CAR-T cell therapy trials | ||
| 30.10. | Bracco invests $230M in first US diagnostic imaging manufacturing facility | ||
| 30.10. | When drug development gets personal | ||
| 30.10. | Chutes & Ladders-Lilly unifies global markets as 36-year vet Patrik Jonsson retires | ||
| 30.10. | Jazz's $820M Actio buyout gives rise to Setara, armed with $90M series A | ||
| 30.10. | AstraZeneca cuts early-phase prostate cancer pipeline | ||
| 30.10. | Molecular Partners to lay off up to 44% of workforce in radiotherapy pivot | ||
| 30.10. | Bambusa shoots past IPO targets as Aspen trims offering | ||
| 30.10. | Sanofi considering 'moonshot' treatments as M&A targets to survive Dupixent patent cliff | ||
| 30.10. | Roche launches differential diagnosis test for mesothelioma | ||
| 29.10. | Connected clinical research: from fragmentation to progress | ||
| 29.10. | Eli Lilly scraps phase 2 Alzheimer's program after drug falls short of expectations | ||
| 29.10. | The cost of waiting: What reaching clinical proof-of-concept sooner means for biotech cash burn |